Antimicrobial Resistance in the Intensive Care Unit
Top Cited Papers
- 15 January 2016
- journal article
- review article
- Published by SAGE Publications in Journal of Intensive Care Medicine
- Vol. 32 (1), 25-37
- https://doi.org/10.1177/0885066615619895
Abstract
Bacterial infections are a frequent cause of hospitalization, and nosocomial infections are an increasingly common condition, particularly within the acute/critical care setting. Infection control practices and new antimicrobial development have primarily focused on gram-positive bacteria; however, in recent years, the incidence of infections caused by gram-negative bacteria has risen considerably in intensive care units. Infections caused by multidrug-resistant (MDR) gram-negative organisms are associated with high morbidity and mortality, with significant direct and indirect costs resulting from prolonged hospitalizations due to antibiotic treatment failures. Of particular concern is the increasing prevalence of antimicrobial resistance to β-lactam antibiotics (including carbapenems) among Pseudomonas aeruginosa and Acinetobacter baumannii and, recently, among pathogens of the Enterobacteriaceae family. Treatment options for infections caused by these pathogens are limited. Antimicrobial stewardship programs focus on optimizing the appropriate use of currently available antimicrobial agents with the goals of improving outcomes for patients with infections caused by MDR gram-negative organisms, slowing the progression of antimicrobial resistance, and reducing hospital costs. Newly approved treatment options are available, such as β-lactam/β-lactamase inhibitor combinations, which significantly extend the armamentarium against MDR gram-negative bacteria.Keywords
This publication has 69 references indexed in Scilit:
- Efficacy and safety of ceftazidime–avibactam versus imipenem–cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized studyCurrent Medical Research and Opinion, 2012
- Audit and Feedback to Reduce Broad-Spectrum Antibiotic Use among Intensive Care Unit Patients A Controlled Interrupted Time Series AnalysisInfection Control & Hospital Epidemiology, 2012
- In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniaeInternational Journal of Antimicrobial Agents, 2012
- Antimicrobial de‐escalation strategies in hospitalized patients with pneumonia, intra‐abdominal infections, and bacteremiaJournal of Hospital Medicine, 2012
- An antimicrobial stewardship program improves antimicrobial treatment by culture site and the quality of antimicrobial prescribing in critically ill patientsCritical Care, 2012
- Mortality and Hospital Stay Associated with Resistant Staphylococcus aureus and Escherichia coli Bacteremia: Estimating the Burden of Antibiotic Resistance in EuropePLoS Medicine, 2011
- Colistin: recent data on pharmacodynamics properties and clinical efficacy in critically ill patientsAnnals of Intensive Care, 2011
- Guidelines for the Prevention of Intravascular Catheter-related InfectionsClinical Infectious Diseases, 2011
- Costs of Bloodstream Infections Caused by Escherichia coli and Influence of Extended-Spectrum-β-Lactamase Production and Inadequate Initial Antibiotic TherapyAntimicrobial Agents and Chemotherapy, 2010
- Extended Spectrum ??-Lactamase (ESBL)-Producing EnterobacteriaceaeDrugs, 2003